Literature DB >> 8734674

Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.

R Ferriols-Lisart1, M Alós-Almiñana.   

Abstract

The effectiveness and safety of once-daily versus several-times-daily aminoglycosides were studied in a meta-analysis. MEDLINE for 1988 to 1995 was searched, and additional studies were identified from review articles and references in retrieved articles. Studies selected for meta-analysis were randomized controlled clinical trials in nonneutropenic adult patients comparing the clinical effectiveness or nephrotoxicity or ototoxicity of once-daily with several-times-daily aminoglycosides. Differences between groups were expressed as odds ratios. The results were combined by the procedure of Mantel and Haenszel, and 95% confidence intervals and exact confidence intervals were computed. An odds ratio smaller than 1 would indicate a lesser likelihood of a given endpoint in the once-daily group, and an odds ratio greater than 1 would indicate a greater likelihood. Eighteen studies involving 2317 patients were included in the meta-analysis. Summary odds ratios were 1.47 for effectiveness (95% CI = 1.13-1.94), 0.56 for ototoxicity (95% CI = 0.26-1.16), and 0.60 for nephrotoxicity (95% CI = 0.40-0.86). A meta-analysis showed that treatment with single daily doses of aminoglycosides seems to be more effective, less nephrotoxic, and as ototoxic as multiple doses daily.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8734674     DOI: 10.1093/ajhp/53.10.1141

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  17 in total

1.  Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration.

Authors:  M LeBrun; L Grenier; P Gourde; M G Bergeron; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

3.  Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies.

Authors:  Tze-Peng Lim; Kevin W Garey; Vincent H Tam
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

4.  Once-daily aminoglycoside therapy: potential ototoxicity.

Authors:  C Singer; C Smith; D Krieff
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

Review 6.  Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Authors:  M L Barclay; C M Kirkpatrick; E J Begg
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

7.  Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

Authors:  C M Kirkpatrick; S B Duffull; E J Begg
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

Review 8.  Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.

Authors:  Yoshiaki Takahashi; Masayuki Igarashi
Journal:  J Antibiot (Tokyo)       Date:  2017-10-25       Impact factor: 2.649

9.  Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Saeed Alqahtani; Manal Abouelkheir; Abdullah Alsultan; Yasmine Elsharawy; Aljawharah Alkoraishi; Reem Osman; Wael Mansy
Journal:  Paediatr Drugs       Date:  2018-06       Impact factor: 3.022

Review 10.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.